A Phase 1 interventional study of Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study. in Influenza (Healthy Volunteers), sponsored by Dalhousie University. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Dalhousie University · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 157 studies in Influenza, Human with a site in Canada — 7 open to participants now, 12 under way, 4 of them phase 3. Influenza, Human · Canada.
Among the 157 studies in Influenza, Human with a site in Canada, this one is the 124th largest by planned enrollment of the 131 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 in phase 1, reaches primary completion later than 7 of the 11 other live ones, and was the 155th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →7 of the 157 studies in Influenza, Human with a site in Canada are open now. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Healthy volunteers
Unity Health Toronto · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
AstraZeneca · Sites in Canada, United States, Argentina and 36 more countries
Ages 18+
UMC Utrecht · Sites in Canada, United States, Australia and 26 more countries
Ages 28 days+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
157 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 37 · Phase 3 42 · Phase 4 24
First in 2005; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 300 across the 131 interventional studies, 241 across the 26 observational. Of the 131 that completed or were terminated, 62 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 157 have an industry lead sponsor. The 10 most frequent:
Dalhousie University is the lead sponsor of 52 studies on the registry; 10 are open to participants now.
Dalhousie University has 7 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
5 of the studies in Influenza, Human with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07314905Phase 3Unity Health TorontoAdaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | 2027-03-31 |
| NCT07240558Phase 3University Health Network, TorontoPandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) | 2027-04-30 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07739719McMaster UniversitySAFE (Self-Administration of Flumist to ImprovE Uptake: A Household-Based Cluster Randomized Trial) | 2027-02-15 |
| NCT07305207Dalhousie UniversityEstablishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness | 2027-06-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 157 studies in Influenza, Human with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall objective is to establish an influenza Controlled Human Infection Model (CHIM) in Canada that can be used to assess the safety and efficacy of candidate vaccines, biologics, and therapeutics targeting influenza viruses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Vital signs** as follows:
If a person is at risk of becoming pregnant, has practiced adequate for 28 days prior to challenge, and has a negative pregnancy test on the screening day and the day before influenza A/H3N2 challenge (Check-in Day) and has agreed to continue adequate contraception until 60 days after challenge.
Risk of pregnancy is defined as any individual assigned female at birth or with reproductive capacity who is sexually active with individuals with sperm-producing capabilities. Individuals who have received the following are considered to not have reproductive capacity:
Adequate contraception is defined as a contraceptive method with a failure rate of \<1% per year when used consistently and correctly and, when applicable, in accordance with the product label. Examples include the following:
Exclusion Criteria:
Underlying cardiac conditions including:
Living with, working with, or in close contact with children less than 6 months of age, or a household member(s) highly recommended to receive an annual influenza vaccination by NACI**** and that have not been immunized with influenza vaccine within the last year or immunized less than 3 weeks prior to challenge.
****Individuals that are highly recommended by NACI to receive an influenza vaccine and potentially at risk include the following (52): (52):
i. Cardiac or pulmonary disorders (including bronchopulmonary dysplasia, cystic fibrosis and asthma) ii. Diabetes mellitus and other metabolic diseases iii. Cancer, immune compromising conditions (due to underlying disease, therapy, or both, such as solid organ transplant or hematopoietic stem cell transplant recipients) iv. Renal disease v. Anemia or hemoglobinopathy vi. Neurologic or neurodevelopmental conditions (includes neuromuscular, neurovascular, neurodegenerative, neurodevelopmental conditions and seizure disorders [and, for children, includes febrile seizures and isolated developmental delay], but excludes migraines and psychiatric conditions without neurological conditions) vii. Morbid obesity (defined as (BMI) ≥ 40 kg/m2) viii. Children six months to 18 years of age undergoing treatment for long periods with acetylsalicylic acid, because of the potential increase of Reye syndrome associated with influenza c. All individuals who are pregnant d. All individuals of any age who are residents of nursing homes and other chronic care facilities e. Adults 65 years of age and older f. Indigenous Peoples
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be inoculated intranasally with a single dose of the A/H3N2 challenge virus or placebo
Biological: Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study.
Participants will be inoculated intranasally with a single dose of the A/H3N2 challenge virus or placebo
Biological: Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study.
Participants will be inoculated intranasally with a single dose of the A/H3N2 challenge virus or placebo
Biological: Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study.
Drug page: Influenza A virus subtype H3N2Studies of Influenza A virus subtype H3N2Influenza A virus subtype H3N2 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants will be inoculated intranasally with a single dose of the A/H3N2 challenge virus or placebo
Symptomatic influenza-virus infection
Viral shedding (as determined by a detectable quantitative RT-qPCR result on at least two days and/or at least one positive culture) beginning 24 hours after challenge (Study Day 2) until Study Day 8 and a cumulative symptom score of ≥6 from daily component symptoms computed across any consecutive 5-day window starting on Study Day 2 up to Study Day 8 post-challenge using a Modified Jackson Score (MJS).
Time frame: Study Day 2 until Study Day 8
Compare rates of symptomatic influenza-virus infection across doses administered.
Rate of symptomatic influenza-virus infection at each challenge dose group administered
Time frame: Study Day 1 up to Study Day 29
Establish the safety profile of a live recombinant influenza strain RG-A/Texas/71/2017 (H3N2, Clade 3C3a) following challenge in healthy adult volunteers.
Percent of unsolicited adverse events (AEs) reported from challenge to Study Day 29. Percent of solicited AEs, specifically Grade 3 or 4 adverse reactions (ARs), defined as signs and symptoms of influenza reported from challenge to Study Day 29. Percent of medically attended adverse events (MAAEs) reported from challenge to Study Day 57. Percent of serious adverse events (SAEs) reported from challenge to Study Day 85. Percent of influenza disease with serious complications (Adverse events of special interest (AESI)) reported from challenge to Study Day 29.
Time frame: Study Day 1 up to Study Day 85
Assess the viral shedding
Percent of participants within a challenge dose group with detected viral shedding in NPSs post-challenge from Study Day 2 onwards using culture and/or RT-qPCR.
Time frame: Study Day 1 up to Study Day 85
Assess the peak viral load
Magnitude of viral shedding post-challenge in each participant, defined as the peak viral load in NPSs from Study Day 2 onwards using RT-qPCR.
Time frame: Study Day 1 up to Study Day 85
Measure the duration of the viral shedding
Duration of viral shedding defined as the number of days from first positive RT-qPCR to last positive RT-qPCR where virus is detected in NPSs post-challenge from Study Day 2 onwards.
Time frame: Study Day 1 up to Study Day 85
Determine the timing, magnitude, and nature of humoral immune responses (hemagglutinin inhibition (HAI) and microneutralization (MN) titers) post-challenge.
Percent of participants with serological conversion defined as a minimum 4-fold rise in post-challenge serum antibodies (by HAI ) to influenza infection at Study Days 15, 29, 57, and 85 post-challenge compared to baseline.
Time frame: Study Day 1 up to Study Day 85
Evaluate the association of culture and/or RT-qPCR-positivity with symptomatic influenza-virus infection.
Correlation of virus culture and virus RT-qPCR with assigning symptomatic influenza-virus infection as the clinical outcome.
Time frame: Study Day 1 up to Study Day 8
Explore the perspectives of Investigators and staff in fostering equitable, diverse, inclusive, and accessible (EDIA) participation in CHIM trials through a qualitative study using questionnaires
Obtain and summarize viewpoints of Investigators and staff through questionnaires on participant equity, diversity, inclusion, and accessibility in CHIM trials.
Time frame: Study Day 1 up to Study Day 85
Determine optimal collection time points for biological specimens to assess mucosal and systemic cellular responses to influenza infection (in nasopharyngeal swabs (NPSs), nasal washes (NWs), serum, saliva secretions, peripheral blood) post-challenge.
Peak magnitude in unit of detection or unit of concentration (e.g., antibody titer), among all study days on which the samples are collected and tested.
Time frame: Study Day 1 up to Study Day 85
Compare detection of virus by culture and by RT-qPCR.
Correlation of virus culture and virus RT-qPCR with determining positive infection status by detection of viral shedding in participants challenged with virus.
Time frame: Study Day 1 up to Study Day 8
Evaluate effects of age, sex, gender, ethnicity, baseline antibody titers, and prior receipt of seasonal influenza vaccine on SII.
Correlation of age, sex, gender, ethnicity, baseline antibody titers, and prior receipt of seasonal influenza vaccine with assigning SII as the clinical outcome.
Time frame: Study Day 1 up to Study Day 85
Describe serum neuraminidase inhibition (NAI) antibody responses post-challenge
Percent of participants with serological conversion defined as a minimum 4-fold rise in post-challenge NAI serum antibodies to influenza infection at Study Days 15, 29, 57, and 85 post-challenge compared to baseline.
Time frame: Study Day 1 up to Study Day 85
Evaluate mucosal IgA immune response at baseline and post-challenge.
Percent of participants with increased nasal IgA from baseline to latest time points available post-challenge.
Time frame: Study Day 1 up to Study Day 85
Evaluate serum and mucosal cytokine and chemokine levels at baseline and post-challenge.
Percent of participants with change in levels of A/Texas/71/2017/H3N2 induced systemic and mucosal cytokine and chemokine responses from baseline to time points available post-challenge.
Time frame: Study Day 1 up to Study Day 85
Determine the timing of cellular immune responses at baseline and post-challenge and correlate with the clinical status of participants
Time of detection, by Study Day, of immune response(s) associated with the different types of immune cells, or cell subsets.
Time frame: Study Day 1 up to Study Day 85
Determine the magnitude of cellular immune responses at baseline and post-challenge and correlate with the clinical status of participants.
Peak magnitude, by Study Day, of immune response(s) associated with the different types of immune cells, or cell subsets.
Time frame: Study Day 1 up to Study Day 85
Determine the nature of cellular immune responses at baseline and post-challenge and correlate with the clinical status of participants
Percent of participants within a challenge dose group with immune response(s) associated with the different types of immune cells, or cell subsets. Percent of participants within a clinical outcome (Non-infected, Asymptomatic, or SII) with immune response(s) associated with the different types of immune cells, or cell subsets.
Time frame: Study Day 1 up to Study Day 85
Compare the clinical features of four groups of participants
Proportions and Generalized Linear Mixed Models (GLMM) of solicited influenza signs symptoms (individually and grouped by body system) plotted over days post-challenge, comparing the four groups of participants while controlling for age, sex, gender, serostatus, and ethnicity, where feasible
Time frame: Study Day 1 up to Study Day 85
Explore alternative case definitions (e.g., mild to moderate influenza disease, influenza like illness) and clinical assessment tools (i.e., Modified Jackson Score, FLU-PRO) for symptomatic RT-qPCR-positive influenza infection.
Correlation of different case definitions of influenza disease using different clinical assessment tools with symptomatic RT-qPCR -positive influenza infection.
Time frame: Study Day 1 up to Study Day 85
Assess the association of human leukocyte antigen (HLA) class I and II alleles with clinical, immune and virologic outcomes
Correlation of (HLA) class I and II alleles with clinical, immune, and virologic outcomes
Time frame: Study Day 1 up to Study Day 85
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.
Of 54 non-industry phase 1 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 12 months is below that.
Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Influenza A virus subtype H3N2
Dalhousie University